Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Study of the Safety and Efficacy of Combination Treatment With REP 2139-Ca and Pegasys™ in Patients With Hepatitis B / Hepatitis D Co-infection

NCT02233075 is registered in ClinicalTrials.gov with Replicor Inc. as lead sponsor.

NCT NCT02233075
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02233075 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Study of the Safety and Efficacy of Combination Treatment With REP 2139-Ca and Pegasys™ in Patients With Hepatitis B / Hepatitis D Co-infection
Lead sponsor
Replicor Inc.
Phase
Phase 2
Overall status
Completed
Start date
September 30, 2014
Completion date
May 31, 2017
Enrollment
12 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

chronic hbv infection (hbeag negative)